|
 |
| REVIEW ARTICLE |
|
| Year : 2019 | Volume
: 40
| Issue : 2 | Page : 75-78 |
|
|
Gut microbiota: One of the new frontiers for elucidating fundamentals of Vipaka in Ayurveda
Anagha Vishwas Ranade1, Amey Shirolkar2, Sharad Daulatrao Pawar3
1 Research Officer (Ayu), Department of Pharmacology, Regional Ayurved Institute for Fundamental Research, Pune, Maharashtra, India
2 Department of Biochemistry, National Centre for Cell Sciences, Pune, Maharashtra, India
3 Research Officer (Pharmacology), Department of Pharmacology, Regional Ayurved Institute for Fundamental Research, Pune, Maharashtra, India
| Date of Submission | 04-Jul-2018 |
| Date of Decision | 04-Apr-2019 |
| Date of Acceptance | 03-Oct-2019 |
| Date of Web Publication | 20-Mar-2020 |
Correspondence Address:
Sharad Daulatrao Pawar
Regional Ayurved Institute for Fundamental Research, Pune - 411 038, Maharashtra
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ayu.AYU_210_18
 Abstract | | |
With the increasing resurgence of Ayurvedic medicine in recent years, a lot of focus is laid on pharmacokinetics of herbs in arresting disease pathology. Ayurveda has enlisted some fundamentals in relation to drug pharmacokinetics, namely Rasa (perception), Virya (potency), Vipaka (postdigestive effect), Guna (properties), and Prabhava (special effect). In recent years, research has emphasized the role of gut microbiota in human health and metabolic processes. A thorough review was done to understand the role of microbiota in drug metabolism if any. The holistic mechanism of gut microbiota coincides to some extent, with the doctrines of Ayurveda in the context of pharmacodynamics and pharmacokinetics. This discussion is a thought put forth with an aim to elucidate the concept of Vipaka vis-a-vis gut microbiota functions.
Keywords: Gut microbiota, pharmacokinetics, Vipaka
How to cite this article:
Ranade AV, Shirolkar A, Pawar SD. Gut microbiota: One of the new frontiers for elucidating fundamentals of Vipaka in Ayurveda. AYU 2019;40:75-8 |
| Introduction | |  |
Gut microbiota is an organ by itself, with an extensive metabolic capability and functional plasticity.[1] The gut microbiota maintains a symbiotic relationship with the gut mucosa in a healthy individual and execute substantial metabolic, immunological and gut protective functions.[2] The gut microbiota obtains nutrients from host dietary components and shed epithelial cells.[3]
Food components passing through the phase of mechanical and chemical digestion reach small intestine as well as endogenous compounds such as digestive enzymes and shed epithelial cells associated with mucus, entering the colon become available for fermentation by microbiota.[4] Bacterial conversion of these compounds results in the liberation of various metabolites. Undigested carbohydrates and proteins constitute the major substrates at the disposal of the microbiota.[5] Fermentation of these substrates results in the production of a range of metabolites including short-chain fatty acids (SCFAs), branched-chain fatty acids, ammonia, amines, phenolic compounds and gases, including hydrogen, methane, and hydrogen sulfide. In addition, the intestinal microbiota is involved in the production of B-complex group of vitamins, the activation or inactivation of bioactive food components such as isoflavonoids and plant lignans, the conversion of prodrugs to their bioactive forms, and the transformation of bile acids and xenobiotics.[6]
Human and microbial symbiosis possesses a close link with the diseases of different systems. Various chronic diseases such as inflammatory bowel disease, diabetes mellitus, metabolic syndrome, atherosclerosis, alcoholic liver disease, non-alcoholic fatty liver disease and cirrhosis have been associated with the human microbiota.[7],[8] These anomalies manifest due to the dysbiosis caused in microbiota, and thus, making them a novel therapeutic target.
There is growing evidence that the metabolism of polyphenols by the microbiota can influence their bioactivity; consequently, interindividual variation in microbial metabolism could have significance for the health benefits of phytochemicals.[9] The best example is again the soy isoflavone and daidzein. There is evidence that equol is more bioactive than its parent isoflavone in a range of areas including estrogenic and antiestrogenic activity, antioxidant capacity and potential anticancer effects.[10] The gut microbiota contributes readily in interpersonal variation in drug response in humans.[11],[12]
| Fundamentals of Vipaka | | |
In Ayurveda, pharmacological effect of Ausadha Dravya (drug) has been explained in Dravyaguna on the basis of the theory of Rasapanchaka.[13] It comprises Rasa (perception), Vipaka (postdigestion effect), Guna (quality), Virya (potency) and Prabhava (special effect).[14] These components form an integral part of Ayurvedic pharmacodynamics and pharmacokinetics. The seers have stated that a drug exhibits its action either by its Rasa, Guna, Vipaka, Virya or Prabhav.[15]
Each of these five ascriptions contributes individually in deciding the fate of Dravya (i.e., medicine or food) without disturbing the collective penta-equilibrium. The fundamentals of Vipaka are closely associated with the post assimilation phase of digestion in humans.
Ayurveda describes the physiology of digestion using three stages rightly known as Avasthapaka,[16] wherein sequential changes in the chemical and mechanical nature of Dravya are well documented.
The Avasthapaka basically consists of three phases as per Charaka, namely Madhura (sweet), Amla (sour)and Katu (pungent). The correlation between Avasthapaka and phases of digestion has been reported.[17]
Madhura Avasthapaka
It commences as soon as the food comprising Shadrasa (six tastes) comes in contact with Bodhaka Kapha and continues up to Amashaya (fundus part of stomach). In this process, thin and frothy Kapha is generated. It is often correlated with the breakdown of starch by salivary amylase and partial digestion in the fundal part of the stomach, where polysaccharides are broken down to monosaccharides.
Amlaavasthapaka
Later, the partially digested (Pakva and Apakva) food comes in contact with Amashaya (pyloric part of stomach) with the environment consisting of HCl that facilitates digestion of proteins, and the resultant acidified chyme (Vidagdha) is propelled into duodenum ahead, where Achha Pitta which intermittent secretion in Grahani (duodenum) during Paka (digestion) is produced which is often correlated with secretion of bile.
Katuavasthapaka
When this food byproduct reaches Pakvashaya (large intestine), it gets further metabolized and hydrolyzed by the Agni (metabolic energy), and it takes a bolus form (Paripindita), resulting in formation pungent taste. This stimulates Vata Dosha. This phase is often equated with the last stage of digestion occurring in the colon along with formation of indole, skatole and excretory products.
A lucid discrimination has been mentioned between Vipaka and Avasthapaka although both have numerical similarities by Charaka.[18] Sushruta has quoted two types of Vipaka based on the physical properties (Guna).[19] It stresses more on structural and functional relationships related to Panchamahabhuta configuration.
The Vipaka is the final transformation of food, whereas Avasthapaka is the initial phase. Vipaka commences only after the Avasthapaka has ceased. This has been denoted in the Chakrapani commentary in Ca. Ci. 15/9–11. The term Bhinna Kala (time factor) denotes that these two stages are different.[18] The actual vitiation of Dosha which, in turn, intimates the end of metabolism (Rasa Mala Viveka)[18] is termed as Vipaka. The factors that determine the Vipaka are Dosha, Mala (fecal matter and urine), and the effect on Shukradhatu which is the last tissue in sequential nutrition as per Ayurveda.[20] Thus, Vipaka is closely associated with secretion and absorption functions after the mechanical and chemical digestion. It is quoted as Karma Nishthaya, that is, it manifests its properties at the end of complete digestion of food/drug.[21],[22] Thus, it suggests that Vipaka is an entity which results in food/drug metabolism for tissue nutrition or cellular nutrition. Three specific Vipaka are themselves responsible for some peculiar action (food/drug metabolism at different stages) as per classics.
The studies[23],[24],[25],[26] that have been carried out abiding by the concept of Vipaka includes very few preclinical and clinical documentation that focus on the “Karma Nishthaya” function of Vipaka, which is partially valid. It rightly denotes the impact of drug on Mala Karma, but it is not efficient in validating the metabolism aspects of the drug. These do not wholly suffice the concept as Mala is not the only criterion for deciding Vipaka.
| Gut Microbiota Vis-A-Vis Vipaka | | |
Vipaka commonly referred to as “Karma Nishthaya,“ that is, “postdigestive irreversible process” is closely associated with biotransformation of drug/food caused by microbiota. Bhadanta Nagarjuna has stated that Parinam Lakshano Vipaka which again points towards biotansformation.[27] In Ayurveda, the term “Vi” is Vishishtha, that is, specific, and “Paka” refers to function assigned to Agni (metabolic energy).[28] These microflora themselves are sources of Agni which reside in Mahasrotasa (gastrointestinal tract) and are responsible for the metabolism of drug. Gut microflora in total exhibits certain specificity in ultimate production of SCFAs and other nutrients depending on the quantity and nature of the diet and medicines. Similarly, the Madhura, Amla and Katu Vipaka of drug (food/medicine) have been denoted to possess qualitative degree (Taratama Bhava)[29] depending on the nature of the drug consumed which manifests in Karma (action) of the drug. The overview of gut microbiota functions in food and drug metabolism vis-a-vis Vipaka has been depicted in [Figure 1]. | Figure 1: Overview of gut microbiota functions in food and drug metabolism
Click here to view |
Evidence states that the intestinal microbiota may play an important role in mediating the metabolism and enhancement of bioactivity of many herbs such as ginseng.[30] Gut microbiota surely plays a role in decreasing as well as increasing drug activity.[31]
The conventional approach of drug discovery is to isolate pure bioactive molecules from the medicinal plant extracts and study there pharmacokinetics and metabolism. This is a hindrance to the concept of whole-drug usage in Ayurveda. Basically, the metabolism of herbal medicines is very complex in comparison to single isolates. The above-mentioned concept of Vipaka along with gut microbial interactions with medicinal plants can certainly give new insights into pathway of drug discovery. Exploratory research in this line can surely aid in scientific validation of Vipaka which is one the doctrines of Dravyaguna.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
| References | | |
| 1. | Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D. Role of the normal gut microbiota. World J Gastroenterol 2015;21:8787-803.  |
| 2. | Shi N, Li N, Duan X, Niu H. Interaction between the gut microbiome and mucosal immune system. Mil Med Res 2017;4:14. |
| 3. | Ramakrishna BS. Role of the gut microbiota in human nutrition and metabolism. J Gastroenterol Hepatol 2013;28 Suppl 4:9-17. |
| 4. | Carding S, Verbeke K, Vipond DT, Corfe BM, Owen LJ. Dysbiosis of the gut microbiota in disease. Microb Ecol Health Dis 2015;26:26191. |
| 5. | Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, et al. Host-gut microbiota metabolic interactions. Science 2012;336:1262-7. |
| 6. | Verbeke KA, Boobis AR, Chiodini A, Edwards CA, Franck A, Kleerebezem M, et al. Towards microbial fermentation metabolites as markers for health benefits of prebiotics. Nutr Res Rev 2015;28:42-66. |
| 7. | Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: Human gut microbes associated with obesity. Nature 2006;444:1022-3. |
| 8. | Wang B, Jiang X, Cao M, Ge J, Bao Q, Tang L, et al. Altered fecal microbiota correlates with liver biochemistry in nonobese patients with non-alcoholic fatty liver disease. Sci Rep 2016;6:32002. |
| 9. | Rowland I, Gibson G, Heinken A, Scott K, Swann J, Thiele I, et al. Gut microbiota functions: Metabolism of nutrients and other food components. Eur J Nutr 2018;57:1-24. |
| 10. | Rowland I, Faughnan M, Hoey L, Wähälä K, Williamson G, Cassidy A. Bioavailability of phyto-oestrogens. Br J Nutr 2003;89 Suppl 1:S45-58. |
| 11. | Guthrie L, Kelly L. Bringing microbiome-drug interaction research into the clinic. EBioMedicine 2019;44:708-15. |
| 12. | Kim DH. Gut microbiota-mediated drug-antibiotic interactions. Drug Metab Dispos 2015;43:1581-9. |
| 13. | Kumar A, Dubey SD, Prakas S, Singh P. Principle of Dravyaguna (ayurvedic pharmacology). Biomed Pharmacol J 2011;4:147-52. Available from: http://biomedpharmajournal.org/?p=1785. [Last accessed on 2019 Oct 03]. |
| 14. | Rath SK, Panja AK, Nagar L, Shinde A. The scientific basis of rasa (taste) of a substance as a tool to explore its pharmacological behavior. Anc Sci Life 2014;33:198-202. |
| 15. | Dwivedi L, editor. Charaka Samhita of Agnivesha, Sutra Sthana. Ch. 26, Ver. 71. 1 st ed. Varanasi: Chaukhamba Krishnadas Academy; 2013. p. 501. |
| 16. | Dwivedi L, editor. Charaka Samhita of Agnivesha, Chikitsa Sthana. Ch. 15, Ver. 9-11. 1 st ed. Varanasi: Chaukhamba Krishnadas Academy; 2013. p. 511. |
| 17. | Divya K, Tripathi JS, Tiwari SK. Exploring novel concept of Agni and its clinical relevance. Altern Integr Med 20132(8):1-6. |
| 18. | Dwivedi L, editor. CharakaSamhita of Agnivesha, Chikitsa Sthana. Ch. 15, Ver. 9-11. 1 st ed. Varanasi: Chaukhamba Krishnadas Academy; 2013. p. 512-4. |
| 19. | Acharya YT, editor. Sushruta Samhita of Sushruta, Sutra Sthana. Ch. 40, Ver. 10-11. 1 st ed. Varanasi: Chaukhamba Krishnadas Academy; 2014. p. 178-9. |
| 20. | Dwivedi L, editor. Charaka Samhita of Agnivesha, Sutra Sthana. Ch. 26, Ver. 61-62. 1 st ed. Varanasi: Chaukhamba Krishnadas Academy; 2013. p. 495. |
| 21. | Dwivedi L, editor. Charaka Samhita of Agnivesha. Sutra Sthana. Ch. 26, Ver. 66. 1 st ed. Varanasi: Choukhambha Krishnadas Academy; 2013. p. 499. |
| 22. | Paradkar S, editor. Ashtanga Hridayam of Vagbhatta, Sutra Sthana. Ch. 9, Ver. 20. 7 th ed. Varanasi. Chaukhamba Orientalia; 1982. p. 169. |
| 23. | Mahajan B, Ravishankar B, Remadevi R. Assessment of Vipaka (metabolism) of a new medicinal plant in animal model. Glob J Res Med Plants Indig Med 2014;3:427-34. |
| 24. | Anuruchi J, Solanki SK, Ashok BK, Dwivedi RR. Pharmacological study to assess the vipaka of certain Samana & Vicitra Pratyayarabdha drugs in albino rats. Glob J Res Med Plants Indig Med 2012;1:620-8. |
| 25. | Jadoun A, Dwivedi R. Effect of selected Samana and Vicitra Pratyayarabdha Dravya w.s.r. to Vipaka. Ayu 2013;34:373-8. |
| 26. | Mahalakshmipuram SP, Ramachandran A, Nishteswar K, Chandola HM. A preface study on exploring the pharmacodynamics of curcuma neilgherrensis Wight-A folklore medicine. Indian J Tradit Knowl 2013;12:288-94. |
| 27. | |
| 28. | Vani G, Prasad J. Concept of Agni and Aharapaka (metabolic transformation) in ayurveda. Int Ayurvedic Med J 2013;1:1-7. |
| 29. | Dwivedi L, editor. Charaka Samhita of Agnivesha, Sutra Sthana. Ch. 26, Ver. 63. 1 st ed. Varanasi: Chaukhamba Krishnadas Academy; 2013. p. 495. |
| 30. | Wang HY, Qi LW, Wang CZ, Li P. Bioactivity enhancement of herbal supplements by intestinal microbiota focusing on ginsenosides. Am J Chin Med 2011;39:1103-15. |
| 31. | Li H, He J, Jia W. The influence of gut microbiota on drug metabolism and toxicity. Expert Opin Drug Metab Toxicol 2016;12:31-40. |
[Figure 1]
|
